Inhibitors of spinster homolog 2 (spns2) for use in therapy

A compound according to Formula I:

• wherein
• X is a C6-C10-aryl or 5- to 10-membered heteroaryl (wherein 1 to 4 heteroaryl ring members are independently selected from N, O, and S);
• R1 and R2 are independently selected from the group consisting of H, C1-C6-alkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C3-C8-cycloalkyl, C1-C6-haloalkyl, CN, and halo;
• W is a bond, O, NH, —NHC(O)—, or —O—(N═)C(R)— (wherein R is H or C1-C6-alkyl);
• U is either:
• (A) an optionally fused, bridged, or spiro-fused 6- to 8-membered heterocycloalkyl wherein 2 ring atoms are N, wherein
• V is selected from the group consisting of H, C1-C14-alkyl, C2-C12-alkenyl, (C6-C10)aryl, (C6-C10)heteroaryl, —C1-C10-alkyl-(C6-C10)aryl, —C2-C12-alkenyl-(C6-C10)aryl, —C1-C10-alkyl-(C3-C8)cycloalkyl, -(3- to 14-membered heterocycloalkyl) (wherein 1-4 heterocycloalkyl members are independently selected from N, O, and S), —(C1-C10)alkyl-(3- to 14-membered heterocycloalkyl) (wherein 1-4 heterocycloalkyl members are independently selected from N, O, and S);
• OR
• (B) a monocyclic 4- to 7-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl members are independently selected from N, O, and S), wherein
• V is selected from the group consisting of H, —C1-C14-alkyl, —C1-C10-alkyl-O—(C3-C14)cycloalkyl, —C1-C10-alkyl-O—(C6-C10)aryl, —C1-C10-alkyl-NRx—(C6-C10)aryl, —C1-C10-alkyl-NRxC(O)(C6-C10)aryl, —C1-C10-alkyl-C(O)NRx(C6-C10)aryl, —C2-C12-alkenyl-O—(C6-C10)aryl, —C1-C10-alkyl-O—(C6-C10)heteroaryl (wherein 1 to 4 heteroaryl ring members are independently selected from N, O, and S), and —C2-C12-alkenyl-O—(C6-C10)heteroaryl (wherein 1 to 4 heteroaryl ring members are independently selected from N, O, and S);
• T is —C(O)— or —NRxC(O)—;
• R is H or C1-C6-alkyl;
• m is an integer selected from 0, 1, 2, 3, 4, 5, and 6;
• wherein each alkyl, alkoxy, alkenyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl is optionally substituted with 1-5 substituents independently selected from the group consisting of hydroxy, halo, C1-C6-alkyl, C1-C6-haloalkoxy, C1-C6-haloalkyl, —NR′2, —NHC(O)(OC1-C6-alkyl), —NO2, —CN, oxo, —C(O)OH, —C(O)O(C1-C6-alkyl), —C1-C6-alkyl(C1-C6-alkoxy), —C(O)NH2, C1-C6-alkoxy, C3-C14-cycloalkyl, —C(O)C1-C6-alkyl, —OC1-C6-alkyl, —Si(C1-C6-alkyl)3, —S(O)0-2—(C1-C6-alkyl), C6-C10-aryl, —(C1-C6-alkyl)(C6-C10-aryl), 3- to 14-membered heterocycloalkyl, and —(C1-C6-alkyl)-(3- to 14-membered heterocycle) (wherein 1-4 heterocycle members are independently selected from N, O, and S), and —O(C6-C14-aryl);
• and
• wherein each R′ is independently selected from the group consisting of C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C6-C10-aryl, 3- to 14-membered heterocycloalkyl and —(C1-C6-alkyl)-(3- to 14-membered heterocycloalkyl) (wherein 1-4 ring members are independently selected from N, O, and S), and 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S;
• or a pharmaceutically acceptable salt thereof.